123ArticleOnline Logo
Welcome to 123ArticleOnline.com!
ALL >> General >> View Article

Rznomics: Circular Rna Platform Tech

Profile Picture
By Author: Ben Gross
Total Articles: 248
Comment this article
Facebook ShareTwitter ShareGoogle+ ShareTwitter Share

Rznomics, a biopharmaceutical company, has developed a groundbreaking 'self-circularized RNA structure' platform technology that efficiently generates circular RNA, overcoming the limitations of existing methods.

Circular RNA (circRNA) offers improved stability against nucleases and minimal unwanted immune responses, making it an attractive candidate for vaccines and therapeutics. Rznomics' technology utilizes a unique Tetrahymena trans-splicing ribozyme platform to convert linear RNA into circular RNA through an end-to-end self-targeting and splicing (STS) reaction. Unlike other methods, Rznomics' circularization does not leave unnecessary genetic information in the gene of interest (GOI). The efficiency of the self-circularization process is comparable to other methods, and various optimization strategies can be employed to increase its efficacy, even with long RNA molecules.

The significance of Rznomics' technology lies in its potential for commercialization, enabling more competitive pricing for circRNA vaccines or therapeutics while maintaining efficacy. In vitro transcription initiates the self-circularization ...
... reaction simultaneously, streamlining the purification process. The purified circRNA demonstrates sustained protein expression without unwanted immune responses, outperforming linear RNA with modified nucleotides.

The research was supported by the Ministry of Science & ICT and the National Research Foundation of Korea. Rznomics holds a patent for the 'Self-circularization RNA structure and Platform technology' in South Korea, with applications submitted in the U.S. and other major countries.

Rznomics is a biopharmaceutical company focused on RNA-based gene therapeutic bio-drugs for cancer and incurable diseases. Their core platform technology utilizes an RNA replacement enzyme, trans-splicing ribozyme, to selectively induce therapeutic gene activity in cells expressing target RNA. The company's lead candidate, RZ-001, is intended for treating Hepatocellular Carcinoma & Glioblastoma, with other treatments in the pipeline for Alzheimer's disease and hereditary retinal dystrophy.

More Information : https://www.techdogs.com/tech-news/pr-newswire/rznomics-presents-its-own-circular-rna-platform-technology

Total Views: 40Word Count: 272See All articles From Author

Add Comment

General Articles

1. Unwind In Paradise: Pompano Beachfront Vacation Rentals Await
Author: T Thomas

2. The Best Metal Detector
Author: sam jou

3. Neue Auctions' Fresh & Neue Sale, Mar 2, Features 341 Lots Of Antiques, Fine Art, Sterling, Jewelry
Author: Cynthia Maciejewski

4. Buy Quality Dermal Fillers And Mesotherapy Online

5. Unlocking Business Agility: The Role And Impact Of Agile Coaching
Author: AgileWaters

6. Why Airlines Keep Seats Empty And How You Can Benefit From It
Author: ReservationsAirlines

7. Everything You Must Know About The Riverbend Homes For Sale
Author: Haupt Realty

8. The Ultimate Guide To Styling Gold Body Chains And Two-piece Mini Skirt Sets
Author: In Your Diva

9. Differentiate Between Iso 9001 And Iso 14001
Author: James

10. How To Pick The Best Career For Yourself?
Author: poddarbschool

11. Iptv Bonanza: Laughing Through Channels, Finding Your Perfect Match!
Author: Abhay pandey

12. Cricket Delight: Joining The Fun With Paid Live Hd Streaming!
Author: Eon Smith

13. Best Aluminium Windows Manufacturers In Shimoga
Author: upvscservice

14. Vk Immigration | Best Immigration Consultancy In Chennai
Author: VK Immigration

15. Savoring The Flavor: Top 5 Pub Foods To Delight Your Palate
Author: Raj Vijay

Login To Account
Login Email:
Forgot Password?
New User?
Sign Up Newsletter
Email Address: